Precision Medicine in Oncology®

Like you, I get up every day and look at the stack of journals I know I need to read but cannot imagine when I will find the time.

Owing to the high clinical failure rates, genetically variable tumor characteristics, and skyrocketing drug development costs, the era of traditional blockbuster oncology agents has come to an end.

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.

The phosphatidylinositol 3-kinase pathway is frequently deregulated in cancer at multiple different points, and has therefore emerged as one of the most deeply explored cell-signaling networks in oncogenic research.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the future of lung cancer treatment at the 8th Annual New York Lung Cancer Symposium®

Drug research and development continues to focus on regimens that select therapy according to the pathologic and molecular characteristics of the tumor.

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.

Josep Tabernero, MD, PhD, of Vall d'Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Five lung cancer experts discuss recent advances and current issues surrounding the treatment of non-small cell lung cancer

Amid rapid progress in the treatment of advanced lung cancer, several leading organizations have joined in developing new guidelines for the optimal use of molecular testing to help select patients for therapy with tyrosine kinase inhibitors

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.